Free Trial
NASDAQ:RDHL

RedHill Biopharma (RDHL) Stock Price, News & Analysis

RedHill Biopharma logo
$5.66 -0.03 (-0.53%)
As of 12:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About RedHill Biopharma Stock (NASDAQ:RDHL)

Key Stats

Today's Range
$5.61
$5.83
50-Day Range
$5.51
$8.50
52-Week Range
$5.41
$31.50
Volume
1,207 shs
Average Volume
9,752 shs
Market Capitalization
$7.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RedHill Biopharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
11th Percentile Overall Score

RDHL MarketRank™: 

RedHill Biopharma scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for RedHill Biopharma.

  • Price to Book Value per Share Ratio

    RedHill Biopharma has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.46% of the float of RedHill Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    RedHill Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RedHill Biopharma has recently increased by 9.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    RedHill Biopharma does not currently pay a dividend.

  • Dividend Growth

    RedHill Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.46% of the float of RedHill Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    RedHill Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RedHill Biopharma has recently increased by 9.43%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    RedHill Biopharma has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for RedHill Biopharma this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for RDHL on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added RedHill Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, RedHill Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.81% of the stock of RedHill Biopharma is held by insiders.

  • Percentage Held by Institutions

    Only 7.20% of the stock of RedHill Biopharma is held by institutions.

  • Read more about RedHill Biopharma's insider trading history.
Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Stock News Headlines

A simple pattern that works in any market
Right when most traders were getting bearish, The All-Weather Pattern signaled something different. Following this setup could've turned every $1,000 into $1,770 in just 48 hours. But here's what really gets me excited... You don't need to be glued to your screen all day, no complex formulas, no guessing. Just wait for a stock to close below The All-Weather Pattern, then check if it opens higher the next morning. That's it. While of course I cannot promise future returns or against losses… I've put together a complete breakdown of how this works, including the new stock that’s tending towards The All-Weather Pattern this week.
RedHill Biopharma to Present Opaganib at U.S. Defense Conference
RedHill Biopharma and Duke Collaborate on Opaganib Development
See More Headlines

RDHL Stock Analysis - Frequently Asked Questions

RedHill Biopharma's stock was trading at $6.21 at the beginning of the year. Since then, RDHL shares have decreased by 8.9% and is now trading at $5.66.
View the best growth stocks for 2025 here
.

RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its earnings results on Tuesday, November, 30th. The biotechnology company reported ($500.00) earnings per share for the quarter, missing the consensus estimate of ($480.00) by $20.00. The biotechnology company had revenue of $21.61 million for the quarter, compared to analyst estimates of $23.41 million.

RedHill Biopharma shares reverse split before market open on Tuesday, August 20th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

RedHill Biopharma's top institutional investors include GAMMA Investing LLC (0.40%).

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that RedHill Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and AbbVie (ABBV).

Company Calendar

Last Earnings
11/30/2021
Today
1/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RDHL
Employees
210
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.53 million
Cash Flow
$569.00 per share
Book Value
$40.58 per share

Miscellaneous

Free Float
1,194,000
Market Cap
$7.28 million
Optionable
No Data
Beta
3.69

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:RDHL) was last updated on 1/17/2025 by MarketBeat.com Staff
From Our Partners